剂型
化学
药理学
阿立哌唑
色谱法
口服
医学
药品
制药技术
高效液相色谱法
作者
Mathilde Costas,Hélène Maillot,Clément Boidin,Antony Citterio‐Quentin,Marwane Azizi,Cynthia Barratier,Sandrine Bourgeois,Bertrand Clerc,J. Boisrame
标识
DOI:10.1136/ejhpharm-2026-005230
摘要
Background/objectives Unit-dose repackaging is increasingly used in hospitals to secure medication administration, but removal from original packaging may compromise drug stability. Aripiprazole tablets had previously been listed as unsuitable for use in dose administration aids because of concerns regarding hygroscopicity. Experimental evidence supporting or refuting these recommendations remains scarce. This study aimed to assess the 6 month physicochemical stability of two oral solid dosage forms of aripiprazole - a conventional tablet (CT) and an orally disintegrating tablet (ODT) - following unit-dose repackaging. Methods Five storage conditions were evaluated, reproducing successive steps of our hospital production circuit and open-air indoor exposure. At 1, 3 and 6 months, chemical stability was assessed by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) and physical stability was evaluated through visual and optical inspection, mass variation, resistance to crushing, friability, and in vitro disintegration. Statistical comparisons between repackaged conditions and non-repackaged tablets were performed using two-sided Mann–Whitney tests. Results Aripiprazole content showed no significant decrease under any condition at any timepoint. No tablet failed any pharmacopoeial test. Resistance to crushing decreased significantly from 1 month onwards under most repackaged conditions, with a parallel reduction in disintegration times; all values remained within specifications. Friability stayed below 1.0% with no fracture. Minor speckling was noted under open-air exposure at 6 months without discolouration. Conclusion Both aripiprazole formulations remained stable under the studied hospital storage conditions, supporting the use of automated unit-dose repackaging in controlled hospital settings. These findings provide evidence that may support reassessment of precautionary recommendations discouraging aripiprazole repackaging under controlled hospital storage conditions.
科研通智能强力驱动
Strongly Powered by AbleSci AI